Press Releases for ANDS

Press Releases
ANA773 Demonstrates Significant Antiviral Response in Early Clinical Trial in Hepatitis C Patients
Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results
Anadys Pharmaceuticals, Inc. Announces Pricing of Common Stock and Warrant Offering
Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference - Mar 31 2009 4:37PM
Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
Anadys Pharmaceuticals to Present at the Citi Biotech Day
Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results and Highlights
Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2008 Financial Results
Anadys Pharmaceuticals to Present at the Roth OC Growth Stock Conference
Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
NASDAQ OMX and Leerink Swann to Co-Host HealthCare Industry Forum - Dec 4 2008 9:39AM
ANA598 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C Infection
Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
Anadys Pharmaceuticals to Present at the Needham Focus on Infectious Disease Conference
Anadys Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C Patients in Phase Ib Study
Anadys Pharmaceuticals to Present at Bio Investor Forum
Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Anadys Pharmaceuticals to Present at BIOCOM Investor Conference 2008
Anadys Pharmaceuticals to Report Third Quarter 2008 Financial Results
Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
Anadys Pharmaceuticals to Present at The Merriman Curhan Ford Investor Summit
Anadys Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
Anadys Pharmaceuticals Reports Second Quarter 2008 Financial Results and Highlights
Anadys Pharmaceuticals to Report Second Quarter 2008 Financial Results
Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences - Jun 1 2008 6:49AM
Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights
Anadys Pharmaceuticals to Report First Quarter 2008 Financial Results
Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference - Jun 1 2008 6:47AM